BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GNT Biotech & Medicals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies GNT Biotech & Medicals's drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06497985-2286@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Chidamide: Phase 3 readout est. (NCT06497985)
DESCRIPTION:Chidamide\, phase 3\, Colorectal Cancer.\nStudy: A Study of Tuc
 idinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Color
 ectal Cancer Patients\nEstimated primary completion: 31 May 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/chidamide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06497985
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947967-2286@assetmemo.bio
DTSTAMP:20261121T005023Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Chidamide: Phase 3 readout est. (NCT06947967)
DESCRIPTION:Chidamide\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: Tucid
 inostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymp
 homa With Follicular Helper of T Cell Phenotype\nEstimated primary complet
 ion: December 2032. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 hidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06947967
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
